Roivant Sciences (ROIV) Common Equity (2020 - 2026)

Roivant Sciences has reported Common Equity for 7 years, with the latest figure at $4.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 3.42% year-over-year to $4.5 billion; the trailing twelve-month figure through Mar 2026 stood at $4.5 billion (down 3.42% YoY), and the FY2026 full-year result was $4.5 billion, down 3.42% from the prior year.
• Common Equity for Q1 2026 stood at $4.5 billion, down from $5.0 billion in the prior quarter.
• The five-year high for Common Equity was $6.6 billion in Q4 2023, with the low at $1.3 billion in Q3 2023.
• Historically, Common Equity has averaged $3.8 billion across 5 years, with a median of $4.7 billion in 2025.
• Annual changes were most pronounced in 2022 — Common Equity plunged 37.65% — and 2023, when it jumped 361.38%.
• Roivant Sciences' Common Equity stood at $1.4 billion in 2022, then surged by 361.38% to $6.6 billion in 2023, then decreased by 15.93% to $5.5 billion in 2024, then dropped by 10.15% to $5.0 billion in 2025, then decreased by 8.98% to $4.5 billion in 2026.
• The last three Common Equity figures came in at $4.5 billion (Q1 2026), $5.0 billion (Q4 2025), and $4.8 billion (Q3 2025), per Business Quant data.